Category Research

Korsana Biosciences

Korsana Biosciences Launches with $175 Million to Develop Innovative Neurodegenerative Treatments

Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases Korsana Biosciences, Inc. a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced its emergence…

Read MoreKorsana Biosciences Launches with $175 Million to Develop Innovative Neurodegenerative Treatments
Therapeutics

New Study Highlights Flashpoint Therapeutics’ Breakthrough HPV Cancer Vaccine

Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the power of its Spherical Nucleic Acid (SNA) platform in immuno-oncology.…

Read MoreNew Study Highlights Flashpoint Therapeutics’ Breakthrough HPV Cancer Vaccine
Twist Bioscience

Twist Bioscience Broadens Antibody Discovery Portfolio Through New Bispecific Licensing Deal

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement Twist Bioscience Corporation a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies…

Read MoreTwist Bioscience Broadens Antibody Discovery Portfolio Through New Bispecific Licensing Deal
Newron

Newron Pharmaceuticals Obtains Up to EUR 38 Million to Propel Late-Stage Evenamide Program

Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program Newron Pharmaceuticals S.p.A. a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that…

Read MoreNewron Pharmaceuticals Obtains Up to EUR 38 Million to Propel Late-Stage Evenamide Program
Clinical

Worldwide Clinical Trials Finalizes Acquisition of Catalyst Clinical Research

Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research Worldwide Clinical Trials a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a combined organization…

Read MoreWorldwide Clinical Trials Finalizes Acquisition of Catalyst Clinical Research
Australian

Australian Breast Cancer Innovators Secure $27M in Private Funding Round

Australian Breast Cancer Innovators Close $27M Private Funding Round OncoRes Medical today announced it has closed an AUD $27M private funding round (‘the Funding round’) to progress clinical development and regulatory milestones for its Quantitative Micro-Elastography (QME) Imaging System, Elora™.…

Read MoreAustralian Breast Cancer Innovators Secure $27M in Private Funding Round
PromptCare

Owlet Partners with PromptCare to Expand Distribution of BabySat® Pediatric Pulse Oximeter

Owlet Announces Strategic DME Partnership with PromptCare to Expand Distribution of Pediatric Pulse Oximeter, BabySat® Owlet, Inc. the pioneer of smart infant monitoring, today announced a new strategic partnership with PromptCare, a leading national respiratory services and durable medical equipment (DME)…

Read MoreOwlet Partners with PromptCare to Expand Distribution of BabySat® Pediatric Pulse Oximeter
Zenix

ZOLL’s New Zenix Monitor/Defibrillator Receives MDR Approval

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU)…

Read MoreZOLL’s New Zenix Monitor/Defibrillator Receives MDR Approval

Pfizer’s Monthly Ultra-Long-Acting Injectable GLP-1 RA Demonstrates Sustained, Significant Weight Loss in Phase 2b Trial

Pfizer’s Monthly Ultra-Long-Acting Injectable GLP-1 RA Demonstrates Sustained and Significant Weight Loss in Phase 2b Trial Pfizer Inc. today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor…

Read MorePfizer’s Monthly Ultra-Long-Acting Injectable GLP-1 RA Demonstrates Sustained, Significant Weight Loss in Phase 2b Trial

FDA Accepts Exelixis’ NDA for Zanzalintinib Combo in Metastatic Colorectal Cancer

Exelixis Announces FDA Acceptance of New Drug Application for Zanzalintinib Combined with Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Exelixis, Inc. today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for…

Read MoreFDA Accepts Exelixis’ NDA for Zanzalintinib Combo in Metastatic Colorectal Cancer

Lilly Chooses Pennsylvania for New Injectable Medicine and Device Manufacturing Facility

Lilly Establishes New Injectable Medicine and Device ManufacturingLilly Chooses Pennsylvania for New Injectable Medicine and Device Manufacturing Facility Eli Lilly and Company today announced plans to invest more than $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania. The site…

Read MoreLilly Chooses Pennsylvania for New Injectable Medicine and Device Manufacturing Facility